Dana-Farber/Brigham and Women's Cancer Center, Biomodels, LLC, Boston, MA, USA.
Division of Oral Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02115, USA.
Support Care Cancer. 2021 Sep;29(9):4939-4947. doi: 10.1007/s00520-021-06108-w. Epub 2021 Mar 13.
Oral mucositis (OM) remains a significant unmet need for patients being treated with standard concomitant chemoradiation (CRT) regimens for head and neck cancers (HNC). OM's pathogenesis is complex and includes both direct and indirect damage pathways. In this paper, the field is reviewed with emphasis on the initiating and sustaining role of oxidative stress on OM's pathobiology. A hypothesis is presented which suggests that based on OM's clinical and biological trajectory, mucosal damage is largely the consequence of cumulative CRT-induced biological changes overwhelming physiologic self-protective mechanisms. Furthermore, an individual's ability to mount and maintain a protective response is dependent on interacting pathways which are primarily determined by a multiplex consisting of genomics, epigenomics, and microbiomics. Effective biologic or pharmacologic OM interventions are likely to supplement or stimulate existing physiologic damage-control mechanisms.
口腔黏膜炎(OM)仍然是接受标准同步放化疗(CRT)方案治疗头颈部癌症(HNC)的患者未满足的重要需求。OM 的发病机制复杂,包括直接和间接损伤途径。本文重点综述了氧化应激对 OM 病理生物学的起始和维持作用。提出了一个假设,即根据 OM 的临床和生物学轨迹,黏膜损伤主要是累积的 CRT 诱导的生物学变化超过生理自我保护机制的结果。此外,个体产生和维持保护反应的能力取决于相互作用的途径,这些途径主要由基因组学、表观基因组学和微生物组学组成的多重因素决定。有效的生物学或药理学 OM 干预措施可能会补充或刺激现有的生理性损伤控制机制。